XCellCure
XCellCure is a biotechnology startup dedicated to revolutionizing the treatment of heart attacks through innovative cardiac panels that include patented prognostic markers. Their products enable personalized, rapid diagnostics to predict and prevent heart tissue damage, aiming to reduce the incidence of fatal heart attacks and improve patient outcomes. The company's mission is to save lives today for a healthier tomorrow by providing tools for early detection, prognosis, and personalized treatment of cardiovascular disease.
Industries
Nr. of Employees
small (1-50)
XCellCure
1801 Park 270 Drive, Suite 350, St. Louis, MO 63146
Patents
Products
AMiAware Human Cardiovascular Disease Microarray (catalog AMIKIT001 / AMIREF002)
A multiplex glass-slide microarray kit and send-out assay for simultaneous quantitative detection of 13 human cardiac protein biomarkers in plasma. Reported assay attributes include 16 wells per slide, quadruplicate antibody spotting, fluorescence detection, sample volume 50–100 µL plasma, reproducibility CV < 20%, and ~3 hour laboratory assay time.
AMiAware Rapid Cardiac Provider Panel (in development, catalog AMIPOCT001)
Planned rapid point-of-care panel intended to quantitatively detect the same 13 cardiac biomarkers from whole blood or heparinized plasma with a targeted assay duration of ~30 minutes for provider use.
AMiAware Rapid Patient Point-of-Care Cardiac Panel (in development, catalog AMIPOCT002)
Planned patient-facing point-of-care panel intended to measure 13 cardiac biomarkers from a finger-prick sample (~20 µL whole blood) with a targeted assay duration of ~15 minutes and electronic result transmission to a clinician.
AMiAware Human Cardiovascular Disease Microarray (catalog AMIKIT001 / AMIREF002)
A multiplex glass-slide microarray kit and send-out assay for simultaneous quantitative detection of 13 human cardiac protein biomarkers in plasma. Reported assay attributes include 16 wells per slide, quadruplicate antibody spotting, fluorescence detection, sample volume 50–100 µL plasma, reproducibility CV < 20%, and ~3 hour laboratory assay time.
AMiAware Rapid Cardiac Provider Panel (in development, catalog AMIPOCT001)
Planned rapid point-of-care panel intended to quantitatively detect the same 13 cardiac biomarkers from whole blood or heparinized plasma with a targeted assay duration of ~30 minutes for provider use.
AMiAware Rapid Patient Point-of-Care Cardiac Panel (in development, catalog AMIPOCT002)
Planned patient-facing point-of-care panel intended to measure 13 cardiac biomarkers from a finger-prick sample (~20 µL whole blood) with a targeted assay duration of ~15 minutes and electronic result transmission to a clinician.
Services
Sample processing and analysis of the multiplex cardiac biomarker microarray at a company-operated laboratory as a send-out diagnostic service.
Sample processing and analysis of the multiplex cardiac biomarker microarray at a company-operated laboratory as a send-out diagnostic service.
Expertise Areas
- Biomarker discovery and validation
- Multiplex immunoassay development
- Point-of-care diagnostic development
- Assay validation and analytical performance
Key Technologies
- Antibody microarrays
- Fluorescence microarray detection (laser scanner)
- Multiplex immunoassays
- Microarray manufacturing and spotting
News & Updates
XCellCure partnered with RayBiotech to develop a diagnostic kit that detects early events leading to cardiovascular disease and myocardial infarction, utilizing innovative biomarkers and antibody array technology.
XCellCure's microarray panels provide critical information for early detection and prognosis of heart attacks, aiming to reduce fatalities and improve treatment decisions.
XCellCure partnered with RayBiotech to develop a diagnostic kit that detects early events leading to cardiovascular disease and myocardial infarction, utilizing innovative biomarkers and antibody array technology.
XCellCure's microarray panels provide critical information for early detection and prognosis of heart attacks, aiming to reduce fatalities and improve treatment decisions.